common.study.topics.clinical

Dosage and Treatment of Advanced Solid Tumors

common.study.values.description

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - BMS-986226

specified dose on specified days

Biological - Nivolumab

specified dose on specified days

Biological - Ipilimumab

specified dose on specified days

Biological - Tetanus Vaccine

specified dose on specified days

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

common.study.values.clinical-trial-id

NCT03251924

participant.views.study.view.id

Xe0zXb